EA201201570A1 - Способы приготовления инъекционных композиций пролонгированного действия - Google Patents

Способы приготовления инъекционных композиций пролонгированного действия

Info

Publication number
EA201201570A1
EA201201570A1 EA201201570A EA201201570A EA201201570A1 EA 201201570 A1 EA201201570 A1 EA 201201570A1 EA 201201570 A EA201201570 A EA 201201570A EA 201201570 A EA201201570 A EA 201201570A EA 201201570 A1 EA201201570 A1 EA 201201570A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
lactic
prolonged action
preparing injection
injection compositions
Prior art date
Application number
EA201201570A
Other languages
English (en)
Other versions
EA024211B1 (ru
Inventor
Ибон Гутьерро Адурис
Мария Тереса Гомес Очоа
Original Assignee
Лабораториос Фармасеутикос Рови, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораториос Фармасеутикос Рови, С.А. filed Critical Лабораториос Фармасеутикос Рови, С.А.
Publication of EA201201570A1 publication Critical patent/EA201201570A1/ru
Publication of EA024211B1 publication Critical patent/EA024211B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Инъекционные композиции пролонгированного действия, содержащие биосовместимый полимер, который представляет собой полимер или сополимер на основе молочной кислоты и/или молочной и гликолевой кислоты, имеющий соотношение мономеров молочной к гликолевой кислоте в диапазоне от 48:52 до 100:0, со смешивающемся с водой растворителе, имеющем дипольный момент около 3,7-4,5 D, и коэффициентом диэлектрической проницаемости между 30 и 50, и лекарственное средство, которое находится в образующихся in-situ биоразлагаемых имплантатах, позволяют поддерживать терапевтический уровень препарата в плазме с момента его введения и на протяжении по крайней мере до 14 дней.
EA201201570A 2010-05-31 2011-05-31 Способы приготовления инъекционных композиций пролонгированного действия EA024211B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382153.4A EP2394663B1 (en) 2010-05-31 2010-05-31 Compositions for injectable in-situ biodegradable implants
PCT/EP2011/059001 WO2011151356A2 (en) 2010-05-31 2011-05-31 Methods for the preparation of injectable depot compositions

Publications (2)

Publication Number Publication Date
EA201201570A1 true EA201201570A1 (ru) 2013-09-30
EA024211B1 EA024211B1 (ru) 2016-08-31

Family

ID=43301929

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201570A EA024211B1 (ru) 2010-05-31 2011-05-31 Способы приготовления инъекционных композиций пролонгированного действия

Country Status (21)

Country Link
US (2) US10058504B2 (ru)
EP (2) EP2394663B1 (ru)
JP (1) JP5923493B2 (ru)
CN (1) CN102933234A (ru)
BR (1) BR112012030707A2 (ru)
CA (1) CA2800641C (ru)
CY (1) CY1124783T1 (ru)
DK (1) DK2582395T3 (ru)
EA (1) EA024211B1 (ru)
ES (2) ES2897976T3 (ru)
FI (1) FI2582395T3 (ru)
HR (2) HRP20211853T1 (ru)
HU (3) HUE057236T2 (ru)
LT (2) LT2394663T (ru)
MX (1) MX346167B (ru)
PL (2) PL2394663T3 (ru)
PT (2) PT2394663T (ru)
RS (2) RS64451B1 (ru)
SI (2) SI2394663T1 (ru)
WO (1) WO2011151356A2 (ru)
ZA (1) ZA201209394B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
DK2394664T3 (en) 2010-05-31 2016-09-12 Laboratorios Farmacéuticos Rovi S A Antipsychotic injectable depot composition
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
DK2529756T3 (da) * 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
US8935726B2 (en) 2012-05-11 2015-01-13 Comcast Cable Communications, Llc Generation of dynamic content interfaces
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
KR20180054627A (ko) * 2015-09-21 2018-05-24 테바 파마슈티컬스 인터내셔널 게엠베하 서방형 올란자핀 제제
CN107811967B (zh) * 2016-09-09 2021-08-24 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) 抗寄生虫药物原位固化缓释注射剂及其制备方法
CN109890365A (zh) * 2016-09-23 2019-06-14 戴尔普尔有限公司 小分子治疗剂化合物的组合物
WO2018070940A1 (en) * 2016-10-14 2018-04-19 Nanyang Technological University An injectable composition for localized controlled and sustained delivery system
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
SG11202003537TA (en) * 2017-11-16 2020-05-28 Persica Pharmaceuticals Ltd Linezolid formulations
PE20210047A1 (es) * 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
KR100354270B1 (ko) 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
US5620770A (en) 1995-06-01 1997-04-15 Superior Environmental Products, Inc. Fifth wheel insert, laminate composite and method of construction
ATE318580T1 (de) 1996-12-20 2006-03-15 Alza Corp Gelzusammensetzungen und verfahren
KR100289471B1 (ko) * 1998-01-19 2001-09-17 김충섭 휀타닐계마취제의이식형서방성제제
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE10190041D2 (de) * 2000-01-11 2002-12-05 Roland Bodmeier Implantate, Partikel
US6604561B2 (en) * 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US6565080B1 (en) 2001-12-17 2003-05-20 Hewlett-Packard Development Company, L.P. Imaging media loading guide
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
AU2004219595A1 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
US8343513B2 (en) 2003-07-18 2013-01-01 Oakwood Laboratories, Llc Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8444600B2 (en) * 2003-09-17 2013-05-21 Jae Sang Park Replaceable heating cartridge for use with a warming device for medical treatment
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
RS53890B1 (en) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. STABILIZED POLYMER DELIVERY SYSTEM
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
SE0600876L (sv) * 2006-04-20 2007-10-21 Sandvik Intellectual Property Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
SI2079767T1 (sl) * 2006-10-11 2015-01-30 Tolmar Therapeutics, Inc. Priprava biorazgradljivih poliestrov, ki imajo lastnost majhnega izbruha, s superkritično tekočinsko ekstrakcijo
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
PT2115029E (pt) 2007-02-15 2015-10-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de efeito de libertação imediata reduzido e métodos de produção de polímeros
WO2008123456A1 (ja) * 2007-03-29 2008-10-16 Kyocera Corporation 携帯無線機
HUE030789T2 (en) * 2007-05-18 2017-06-28 Durect Corp Improved depot formulation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US8629172B2 (en) * 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
ES2390439B1 (es) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
DK2394664T3 (en) 2010-05-31 2016-09-12 Laboratorios Farmacéuticos Rovi S A Antipsychotic injectable depot composition
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
SI2529757T1 (sl) 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
DK2529756T3 (da) 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering

Also Published As

Publication number Publication date
WO2011151356A3 (en) 2012-03-22
ZA201209394B (en) 2013-08-28
SI2394663T1 (sl) 2022-02-28
HRP20230890T1 (hr) 2023-11-10
EP2394663A1 (en) 2011-12-14
LT2394663T (lt) 2022-02-10
ES2950857T3 (es) 2023-10-16
RS64451B1 (sr) 2023-09-29
US20180318208A1 (en) 2018-11-08
FI2582395T3 (fi) 2023-08-08
MX346167B (es) 2017-03-08
MX2012013867A (es) 2013-01-24
SI2582395T1 (sl) 2023-10-30
CA2800641C (en) 2018-05-22
LT2582395T (lt) 2023-08-10
PT2582395T (pt) 2023-08-18
CA2800641A1 (en) 2011-12-08
HUE063623T2 (hu) 2024-01-28
EP2582395A2 (en) 2013-04-24
HUE057236T2 (hu) 2022-04-28
RS53205B (en) 2014-06-30
US10058504B2 (en) 2018-08-28
HRP20211853T1 (hr) 2022-03-04
US20130177603A1 (en) 2013-07-11
CN102933234A (zh) 2013-02-13
ES2897976T3 (es) 2022-03-03
DK2582395T3 (da) 2023-08-07
CY1124783T1 (el) 2022-11-25
PL2394663T3 (pl) 2022-02-21
JP2013527213A (ja) 2013-06-27
EA024211B1 (ru) 2016-08-31
US10195138B2 (en) 2019-02-05
EP2394663B1 (en) 2021-10-13
PT2394663T (pt) 2021-11-26
EP2582395B1 (en) 2023-05-10
WO2011151356A2 (en) 2011-12-08
JP5923493B2 (ja) 2016-05-24
PL2582395T3 (pl) 2023-08-21
HUE054922T2 (hu) 2021-10-28
BR112012030707A2 (pt) 2016-11-01

Similar Documents

Publication Publication Date Title
EA201201570A1 (ru) Способы приготовления инъекционных композиций пролонгированного действия
CY1120975T1 (el) Συστημα αποθεματος που περιλαμβανει οξικη γλατιραμερη
CY1114975T1 (el) Σκευασμα εμφυτευματος παλιπεριδονης
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
CY1124369T1 (el) Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης
IN2014DN02047A (ru)
NZ604342A (en) Antipsychotic injectable depot composition
NZ604026A (en) Injectable flowable composition comprising buprenorphine
EA201691884A1 (ru) Получение загруженных пептидом микросфер на основе plga с характеристиками контролированного высвобождения
BR112013011282A2 (pt) formulações baseadas em ácido hialurônico
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
MX2013012934A (es) Nanoparticulas polimericas para el suministro de farmacos.
CY1125157T1 (el) Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη
WO2015130602A3 (en) Sustained release composition using biobased biodegradable hyperbranched polyesters
RU2012145811A (ru) Композиции и способы улучшенного удержания фармацевтической композиции на участке местного введения
RU2013149900A (ru) Биологически разлагаемая полимерная композиция с высокой деформируемостью
EA201890698A1 (ru) Химически инертный термоплавкий клей с улучшителем времени схватывания
UA114088C2 (xx) Лікарська композиція з пролонгованим вивільненням для ін'єкцій
RU2014104678A (ru) Имплантируемый стент
RU2009149682A (ru) Применение синтезированных в плазме полимеров, являющихся производными пиррола для нейропротекции и восстановления соединения в центральной нервной системе
MX2020006188A (es) Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada.
PE20121481A1 (es) Formulacion de liberacion sostenida
EA201000678A1 (ru) Фармацевтические композиции, содержащие антагонисты брадикинина и гиалуроновую кислоту, и их применения
WO2012064087A3 (ko) 아나스트로졸 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물
WO2015161841A3 (de) Injizierbare und implantierbare trägersysteme auf basis von modifizierten poly(dikarbonsäure-polyol estern) zur kontrollierten wirkstofffreisetzung